TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRCA1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.
Sinclair
Colleen S
CS
Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
Adem
Camilo
C
Naderi
Ali
A
Soderberg
Cheryl L
CL
Johnson
Michele
M
Wu
Kangjian
K
Wadum
Linda
L
Couch
Vicki L
VL
Sellers
Thomas A
TA
Schaid
Daniel
D
Slezak
Jeffrey
J
Fredericksen
Zach
Z
Ingle
James N
JN
Hartmann
Lynn
L
Jenkins
Robert B
RB
Couch
Fergus J
FJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D005784:Gene Amplification; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D020825:T-Box Domain Proteins / Q000235:genetics*
C097348:T-Box Domain Protein 2; D020825:T-Box Domain Proteins